title: Cyclophilin A interacts with domain II of hepatitis C virus NS5A and stimulates RNA binding in an isomerase-dependent manner.
abstract: NS5A plays a critical, yet poorly defined, role in hepatitis C virus genome replication. The protein consists of three domains, each of which is able to bind independently to the 3' untranslated region (UTR) of the viral positive strand genomic RNA. The peptidyl-prolyl isomerase cyclophilin A (CypA) binds to domain II, catalyzing cis-trans isomerization. CypA inhibitors such as cyclosporine (CsA) have been shown to inhibit hepatitis C virus (HCV) replication. We show here that CypA stimulated domain II RNA binding activity, and this stimulation was abrogated by CsA. An isomerase mutant of CypA (H126Q) failed to bind to domain II and did not stimulate RNA binding. Finally, we demonstrate that the RNA binding of two domain II mutants, the D316E and D316E/Y317N mutants, previously shown to exhibit CypA independence for RNA replication, was unaffected by CypA. This study provides an insight into the molecular mechanism of CypA activity during HCV replication and further validates the use of CypA inhibitors in HCV therapy.
authors: Institute of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Mount Preston Street, Leeds LS2 9JT, United Kingdom.
authors: Toshana L
authors: TL
authors: Foster
authors: Philippe
authors: P
authors: Gallay
authors: Nicola J
authors: NJ
authors: Stonehouse
authors: Mark
authors: M
authors: Harris
references: J Biol Chem. 2009 Jun 19;284(25):16998-17005
references: 19380579
references: J Virol. 2010 Sep;84(18):9267-77
references: 20592076
references: Mol Cell. 2005 Jul 1;19(1):111-22
references: 15989969
references: Biochemistry. 2007 Oct 16;46(41):11550-8
references: 17880107
references: Hepatology. 2009 Nov;50(5):1638-45
references: 19821520
references: J Virol. 2010 Dec;84(24):12480-91
references: 20926572
references: J Biol Chem. 2004 Nov 19;279(47):48576-87
references: 15339921
references: Curr Opin Investig Drugs. 2010 Aug;11(8):911-8
references: 20721833
references: Mol Cells. 2006 Aug 31;22(1):13-20
references: 16951545
references: J Biol Chem. 2005 Oct 28;280(43):36417-28
references: 16126720
references: PLoS Pathog. 2009 Aug;5(8):e1000546
references: 19680534
references: Lancet Infect Dis. 2005 Sep;5(9):558-67
references: 16122679
references: PLoS One. 2010 Oct 27;5(10):e13687
references: 21060866
references: J Biol Chem. 2009 May 15;284(20):13589-13601
references: 19297321
references: PLoS Pathog. 2010 Sep 23;6(9):e1001118
references: 20886100
references: J Virol. 2006 May;80(9):4510-20
references: 16611911
references: J Biol Chem. 2003 May 16;278(20):17775-84
references: 12621033
references: J Virol. 2009 Jul;83(13):6554-65
references: 19386705
references: J Hepatol. 2010 Jul;53(1):50-6
references: 20451281
references: Bioinformatics. 2005 Feb 1;21(3):379-84
references: 15377502